When you engage AbbVie Contract Manufacturing, you’re getting more than a CMO. You fully access the capabilities of a highly experienced biopharmaceutical company. You know that your project will benefit from our broad range of capabilities and portfolio of state-of-the-art facilities in North America and Europe. Most of all, you know that your project will be reliably served by a business with a trusted reputation for innovation, reliability, compliance and delivery.

AbbVie Contract Manufacturing has over 40 years of experience as a pharmaceutical developer and manufacturer. We help domestic and global companies develop, scale, and commercially manufacture pharmaceutical products drawing on our extensive experience to accelerate time to market. Our services are comprised of:

Biologics | ADC | Potent | Drug Product | Fermentation | Hot Melt Extrusion | Sterile Fill/Finish | Pre-filled Syringe | APIs

As an embedded CMO, AbbVie Contract Manufacturing allows greater access to global manufacturing and a variety of scales and technologies. We handle your pharmaceutical products with the same dedication as our own and our partners realize the unique benefits of trusting a leading biopharmaceutical company with their contract manufacturing needs.

Above all, your project will benefit from a premier scientific team with the experience to meet complex challenges with demonstrative successful proven solutions.

As a multi-year recipient of Life Science Leader annual CMO leadership award for quality, innovation, productivity and reliability, AbbVie is ready to bring our experience to your business.


AbbVie has a 125-year history of patient care, as well as a focus on developing advanced therapies to address some of the world’s most complex disease states.

AbbVie’s expanded focus on biologics and targeted medicine allows us to use our knowledge and expertise to address difficult conditions that affect significant patient populations. Our priority is our patients, helping them lead healthier lives.

Founded on January 1 of 2013, AbbVie is a renowned biopharmaceutical company that began as part of the pharmaceutical leader, Abbott, which was founded in 1888 by Dr. Wallace Abbott to provide better care for patients.

At AbbVie, we have the expertise of a proven pharmaceutical leader and the focus and passion of an entrepreneur and innovator. The result is something rare in health care today — a global biopharmaceutical company that has the ability to discover and advance innovative therapies while meeting the health needs of people and societies around the globe.


AbbVie’s new aseptic fill / finish vial line located in Sligo, northwest Ireland, is approximately 130 miles from Dublin. This state-of-the-art line supports lyophilization for potent and biologics along with liquid fill vials. Equipment installation is underway with production commencing H2 2020.

Ten state-of-the-art commercial manufacturing facilities in North America and Europe. AbbVie Contract Manufacturing offers a wide range of global contract manufacturing capabilities.

Whether you’re developing a new chemical entity or a first-to-market generic, precise dosing and drug delivery is vital for success. Regulatory agencies and clinicians want to see well-characterized, reliable doses with good bioavailability. Patients/consumers often favor a controlled release dosage form, with easy-to-use packaging and taste-free consumption. Drug developers increasingly need to deliver on all these fronts and more, without compromising speed-to-market, in order to manage a successful pharmaceutical program. Direct benefits of pharmaceutical outsourcing and contract manufacturing allows developers to access both state-of-the-art technology and accelerate your time to market.

Fermentation is a critical step in both drug and toll manufacturing, as companies look to produce the core compounds that form their eventual products. While it is possible to undertake this in-house, the expertise contract fermentation services provide can improve the quality, affordability, speed and scalability of your program.

High potency manufacturing is an expanding field with a unique set of challenges. Safety remains a primary concern for those handling cytotoxic drug products, as well as the clinicians and patients down the line. Beyond safety, pharmaceutical companies need to plan ahead for how they will manufacture high potency drugs at scale, distributing the end-products worldwide with secure supply chains in place.

With patients’ lives at the end of the pipeline, biologics contract manufacturing needs to be safe, reliable and consistent in supply. The developers of these large molecule drugs, however, are also operating in a highly competitive space. Speed-to-market is imperative, along with efficient processes and low costs. A lot of this will rest on the quality of the cell line development and the expertise of the biologics CMO you choose.

When selecting AbbVie Contract Manufacturing, you are partnering with a leading developer and manufacturer focused on accelerating and mitigating risks to program timelines and on efficiently fast-tracking your program to completion. AbbVie’s mAb and ADC state-of-the-art facility and expert scientific team are located in Worcester, Massachusetts, where we specialize in treating your product as our own and have demonstrated the capability to optimize success from innovation through commercialization. In addition to our expertise, our customers also benefit from a simplified supply chain as both mAb and conjugation manufacturing are conveniently located at one site.

Hot melt extrusion (HME) is a proven technology for bioavailability enhancement of poorly soluble API's. Unlike other formulation options, hot melt extrusion technology is solvent-free. By drawing on continuous processing, hot melt extrusion is more economical and can be used for abuse deference and taste masking applications. This can ultimately deliver a higher quality, more marketable pharmaceutical product — in line with your commercialization strategy.

Fill-finish syringe manufacturing is one of the last steps in pharmaceutical commercialization. The goal here is efficiency and sterility. Companies don’t want to waste any of their carefully developed product and they don’t want to distribute poor quality prefilled syringes or contaminated formulas. Once established, high syringe manufacturing standards must then be maintained throughout the drug’s life span, to deliver a reliable supply for patients.

The active pharmaceutical ingredient (API) is the foundation of a final drug product, and a key consideration as you consider contract manufacturing.11



1 N Waukegan Rd.

North Chicago, IL 60064


Phone: 847-938-8524


  • Operational Advantages Of Using Hot Melt Extrusion To Create Amorphous Solid Dispersions

    The limited solubility of many modern drugs frequently translates to low bioavailability, making improved solubility a primary goal of oral dosage formulation development. Low aqueous solubility can be combated through preparation of an amorphous solid dispersion (ASD). This article explores spray drying and hot melt extrusion (HME) which are among the most widely applied technologies for producing ASDs.

  • How Can Working With An Embedded CMO Benefit Your Drug Product?

    The right CMO can expedite market launch, and an embedded CMO offers many advantages over other CMO models, including access to the extensive capabilities and knowhow of the parent organization.

  • The Value Of Expertise In Aseptic Fill Finish Manufacturing Of Biologics

    Aseptic fill finish manufacturing is one of the final but crucial steps between biopharmaceutical development and patient care, and it's especially critical for highly valuable biologic drug substances.

  • What Your CMO Needs To Know About Serialization And Aggregation

    In recent years, the global pharmaceutical industry has been under intense pressure to enhance the safety, security, and continuity of the supply chain. This has required drug manufacturers and a vast range of supply chain partners to work collaboratively to improve supply chain transparency. The goal is to be able to track, trace, and authenticate products, and to assure prescription drug supply from the manufacturer to the patient. Partnering with a CMO that has applied traceability, serialization and aggregation standards across its own operations promises business continuity and speed-to-market that translate to a competitive advantage.

  • CMO As Partners For ADC Process Development, Scale-up, And Optimization

    ADC programs can accelerate through clinical phases rapidly, making early preparation for commercial launch imperative. It's sensible to partner with a CMO with a strong biologics foundation.

  • Is Your Quality Agreement Fit-For-Purpose?

    Partnering with a CDMO requires a policy that addresses management responsibilities, risk management, documentation, change management, CAPA, process performance, and product quality. 

  • How Can Extrusion Benefit Your Pharmaceutical Oral Drug Product?

    Due to its immense adaptability, extrusion has been widely utilized in diverse fields. It is being adopted more recently by the pharmaceutical industry at an unprecedented pace.

  • Keeping Pace With Increasing Biopharmaceutical Manufacturing Demand

    Today’s biologics pipeline is healthy, but forecasts indicate growth so robust the industry risks being ill-equipped to meet demand. Will contract manufacturers to rise to the demand challenge?

  • Optimize Your Lyophilization Process Using Minimal Drug Substance

    Here's how advances in steady-state computer modeling and bench-scale lyophilization practices are driving process optimization with minimal drug substances.

  • Lyophilization Of Highly Potent Drugs: Facility and Equipment Design Elements

    Because scale-up and technology transfer of the lyophilization process is challenging, it is important to develop a comprehensive understanding of critical lyophilization characteristics early on.

  • 5 Steps To Accelerated Biologics Manufacturing And Robust Scale-Up

    A platform approach to process characterization ensures accuracy and results in a consistent product, which facilitates efficient BLA filing and acceleration to commercial scale.

  • Patient-Centricity: A Drug Development Imperative

    Success in biopharmaceutical development is ultimately about facilitating positive patient outcomes. How is patient-centricity influencing the development process today, and what role do CMOs play? 

  • CMC Strategies For The Acceleration Of Commercial-Ready ADC Manufacturing

    The potential for antibody-drug conjugate (ADC) programs to accelerate from early to late stage clinical development highlights the need to establish commercial launch-ready manufacturing early and efficiently.

  • Selecting A CMO: Top Considerations

    Choosing the right contract organization to handle the development and manufacturing of a drug product is of critical importance. Here are tips to ensure a successful outcome.

  • What Dosage Form Provides A Release Drug Control Rate?

    Whether your goal is to increase patient compliance, improve clinical outcomes, or to extend a product’s lifecycle, modified-release dosage forms present a solution to myriad challenges. 

  • How To Increase The Solubility And Bioavailability With Hot Melt Extrusion?

    When executed properly, HME advances poorly soluble compounds in the development pipeline, without adding delays, cost, or significant post-processing activities, and can scale to commercial manufacturing.

  • How To Avoid High Potency API Contamination

    To ensure that employee exposures are kept within accepted limits and protect the environment while containing costs, pharmaceutical companies and their contract partners who manufacture and handle high containment compounds must carefully select equipment, outline processes and procedures, and deploy appropriate containment technologies. Having standards in place for engineering controls is the first line of defense against harm from cross contamination or exposure to the patient, manufacturing employees, or the environment when working with HPAPIs.In this paper learn how to determine exposure potential and select the correct equipment and technology.

  • AbbVie Contract Manufacturing Wins Life Science Leader CMO Awards For The Seventh Year

    “AbbVie is honored to be recognized once again as a top Contract Manufacturer by Life Science Leader,” said Azita Saleki-Gerhardt, Ph.D., President, Operations. “It is a privilege to achieve the top ranking in all six award criteria for the fourth year in a row. We are extremely proud of this achievement, as it recognizes our efforts to provide the highest quality and consistent support and services for our partners and their patients.”

  • Track-And-Trace In The Drug Supply Chain

    Though the timelines may vary, across the globe more and more countries are requiring product identifiers and serialization of prescription drugs — right down to individual salable units. 

  • Q&A Bilayer Tablet Manufacturing

    Bilayer is considerably more convenient for patients due to receive multiple medications or longer-lasting profiles in a single dosage form and has the added benefit of improved patient compliance. This Q&A explores the manufacturing challenges, how to overcome them and considerations when selecting a CDMO for the manufacturing process.

  • Is Your CMO Ready For Serialization And Aggregation?

    While some are waiting for mandates for traceability, serialization, and aggregation, others are recognizing the inevitability of these strategies. Does your CMO have a dedicated traceability operation in place?

  • Avoiding HPAPI Contamination

    Strict regulations regarding the manufacture of HPAPIs require that pharmaceutical companies and CMOs carefully select equipment, outline processes and deploy appropriate containment strategies. 

  • Putting The “Process” Into Process Characterization

    Done correctly, Process Characterization reduces the risk of manufacturing failures and regulatory delays. Scientists at the AbbVie Bioresearch Center (ABC) have established a platform approach to Process Characterization that has been proven effective as it has been used to support the approval of several marketed products.

  • Advantages Of A Lipid-Based Drug Delivery System For Poor Bioavailability Drugs

    There are a number of reasons to choose a Lipid-Based Drug Delivery System over conventional formulation approaches when working with poorly soluble compounds. 

  • Using A CMO To Streamline Process Characterization

    While traditional small molecule drug products usually consist of pure chemical substances that are easily analyzed after manufacture, biologics such as monoclonal antibodies (mAbs) are much more complex. 

  • Fluid Bed Granulation And Melt Granulation In Pharma Manufacturing

    Affording superior reproducibility and control than other granulation techniques, fluid bed granulation and melt granulation can be tightly regulated to produce uniform material with a specified particle size.

  • Tackling The Challenges Of Biologics Development And Manufacturing

    Read why it is critical to have the right manufacturing partner to minimize challenges as a therapies move from discovery to commercialization.

  • Small Molecule Impurities: A Control System Design Challenge For ADCs

    Composed of both antibody and small molecule elements, ADCs have a complex structure from which many different impurities can arise.